Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review

Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review Publisher Pubmed

Talasaz AH^{1, 2, 3} ; Sadeghipour P⁴ ; Aghakouchakzadeh M¹ ; Dreyfus I⁵ ; Kakavand H¹ ; Ariannejad H² ; Gupta A^{5, 6, 7} ; Madhavan MV^{5, 6} ; Van Tassell BW^{3, 8} ; Jimenez D⁹ ; Monreal M¹⁰ ; Vaduganathan M¹¹ ; Fanikos J¹² ; Dixon DL^{3, 8} Show All Authors

Talasaz AH^{1, 2, 3}
Sadeghipour P⁴
Aghakouchakzadeh M¹
Dreyfus I⁵
Kakavand H¹
Ariannejad H²
Gupta A^{5, 6, 7}
Madhavan MV^{5, 6}
Van Tassell BW^{3, 8}
Jimenez D⁹
Monreal M¹⁰
Vaduganathan M¹¹
Fanikos J¹²
Dixon DL^{3, 8}
Piazza G¹¹
Parikh SA^{5, 6}
Bhatt DL¹¹
Lip GYH^{13, 14}
Stone GW^{6, 15}
Krumholz HM^{7, 16, 17}
Libby P¹¹
Goldhaber SZ¹¹
Bikdeli B^{6, 7, 11}

Source: Journal of the American College of Cardiology Published:2021

Abstract

Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management. © 2021 American College of Cardiology Foundation

Related Docs

View other Related Docs

1. Atorvastatin Versus Placebo in Patients With Covid-19 in Intensive Care: Randomized Controlled Trial, The BMJ (2022)

2. Atorvastatin Versus Placebo in Icu Patients With Covid-19: Ninety-Day Results of the Inspiration-S Trial, Thrombosis and Haemostasis (2023)

3. Recent Randomized Trials of Antithrombotic Therapy for Patients With Covid-19: Jacc State-Of-The-Art Review, Journal of the American College of Cardiology (2021)

Experts (# of related papers)

View all Related Experts

Azita Hajhossein Talasaz (11)

Hossein Khalili (5)

Style	Citing Format
MLA	Talasaz AH, et al.. "Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review." Journal of the American College of Cardiology, vol. 78, no. 16, 2021, pp. 1635-1654.
APA	Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, ... Bikdeli B (2021). Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review. Journal of the American College of Cardiology, 78(16), 1635-1654.
Chicago	Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, et al.. "Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review." Journal of the American College of Cardiology 78, no. 16 (2021): 1635-1654.
Harvard	Talasaz AH et al. (2021) 'Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review', Journal of the American College of Cardiology, 78(16), pp. 1635-1654.
Vancouver	Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, et al.. Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review. Journal of the American College of Cardiology. 2021;78(16):1635-1654.
BibTex	@article{ author = {Talasaz AH and Sadeghipour P and Aghakouchakzadeh M and Dreyfus I and Kakavand H and Ariannejad H and Gupta A and Madhavan MV and Van Tassell BW and Jimenez D and Monreal M and Vaduganathan M and Fanikos J and Dixon DL and Piazza G and Parikh SA and Bhatt DL and Lip GYH and Stone GW and Krumholz HM and Libby P and Goldhaber SZ and Bikdeli B}, title = {Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review}, journal = {Journal of the American College of Cardiology}, volume = {78}, number = {16}, pages = {1635-1654}, year = {2021} }
RIS	TY - JOUR AU - Talasaz AH AU - Sadeghipour P AU - Aghakouchakzadeh M AU - Dreyfus I AU - Kakavand H AU - Ariannejad H AU - Gupta A AU - Madhavan MV AU - Van Tassell BW AU - Jimenez D AU - Monreal M AU - Vaduganathan M AU - Fanikos J AU - Dixon DL AU - Piazza G AU - Parikh SA AU - Bhatt DL AU - Lip GYH AU - Stone GW AU - Krumholz HM AU - Libby P AU - Goldhaber SZ AU - Bikdeli B TI - Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review JO - Journal of the American College of Cardiology VL - 78 IS - 16 SP - 1635 EP - 1654 PY - 2021 ER -

Style

Citing Format

MLA

Talasaz AH, et al.. "Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review." Journal of the American College of Cardiology, vol. 78, no. 16, 2021, pp. 1635-1654.

APA

Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, ... Bikdeli B (2021). Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review. Journal of the American College of Cardiology, 78(16), 1635-1654.

Chicago

Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, et al.. "Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review." Journal of the American College of Cardiology 78, no. 16 (2021): 1635-1654.

Harvard

Talasaz AH et al. (2021) 'Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review', Journal of the American College of Cardiology, 78(16), pp. 1635-1654.

Vancouver

Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, et al.. Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review. Journal of the American College of Cardiology. 2021;78(16):1635-1654.

BibTex

@article{ author = {Talasaz AH and Sadeghipour P and Aghakouchakzadeh M and Dreyfus I and Kakavand H and Ariannejad H and Gupta A and Madhavan MV and Van Tassell BW and Jimenez D and Monreal M and Vaduganathan M and Fanikos J and Dixon DL and Piazza G and Parikh SA and Bhatt DL and Lip GYH and Stone GW and Krumholz HM and Libby P and Goldhaber SZ and Bikdeli B}, title = {Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review}, journal = {Journal of the American College of Cardiology}, volume = {78}, number = {16}, pages = {1635-1654}, year = {2021} }

RIS

TY - JOUR
AU - Talasaz AH
AU - Sadeghipour P
AU - Aghakouchakzadeh M
AU - Dreyfus I
AU - Kakavand H
AU - Ariannejad H
AU - Gupta A
AU - Madhavan MV
AU - Van Tassell BW
AU - Jimenez D
AU - Monreal M
AU - Vaduganathan M
AU - Fanikos J
AU - Dixon DL
AU - Piazza G
AU - Parikh SA
AU - Bhatt DL
AU - Lip GYH
AU - Stone GW
AU - Krumholz HM
AU - Libby P
AU - Goldhaber SZ
AU - Bikdeli B
TI - Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review
JO - Journal of the American College of Cardiology
VL - 78
IS - 16
SP - 1635
EP - 1654
PY - 2021
ER -

Science Communicator Platform

Authors

Abstract